Searchable abstracts of presentations at key conferences in endocrinology

ea0004oc3 | Growth regulation and development | SFE2002

Influence of genotype on the endocrine and metabolic control of uncoupling protein (UCP)-2 during the first week of life in neonatal piglets

Mostyn A , Litten J , Perkins K , Symonds M , Clarke L

It is well established that neonatal mortality is greater in the leaner commercial (C) porcine genotypes compared to the ancient Meishan (M) breed, which has a higher percentage of body fat. Piglets do not express UCP1, responsible for heat production in neonatal mammals, although they do express UCP2. The aim of this study was to investigate the endocrine and metabolic control of UCP2 expression between the C and M genotypes.Piglets from 15 C and 15 M l...

ea0023oc4.1 | Oral Communications 4 | BSPED2009

Parahippocampal aberrations in children with GH deficiency: a diffusion tensor imaging study

Webb E A , O'Reilly M , Seunarine K , Clayden J , Dale N , Salt A , Clark C , Dattani M T

Introduction: There is a large body of evidence to suggest that the GH axis plays an important role in brain myelination. However, results from studies in humans with an abnormal GH axis have varied and therefore there remains no consensus as to whether the GH/IGF1 axis plays a significant role in neural development. No previous studies have used diffusion tensor imaging (DTI) a sensitive magnetic resonance imaging (MRI) technique for studying brain white matter tracts, to add...

ea0011p29 | Bone | ECE2006

Evaluation of bone markers and structure in subclinical Cushing’s syndrome

Monesi M , Ambrosio MR , Taroni S , Bondanelli M , Zatelli MC , degli Uberti EC

Overt hypercortisolism causes reduction in bone mass and density. The effects of subclinical Cushing’s syndrome (SCS) on bone markers and structure are still debated. We therefore studied 56 patients with adrenal incidentaloma: group A=35 (20 F 15 M, age 43–79, mean 64.6±1.5; BMI 29.9±0.9 kg/m2) without evidence of hypercortisolism, and group B=21 (10 F 11 M, age 51–76, mean 63.4±1.9, BMI 28.0±1.2 kg/m2) with SCS (i.e. w...

ea0088017 | Abstracts | BES2022

Prolactinomas: our experience in Liège

M Trebillod , L Vroonen , P Petrossians

Introduction: The true prevalence of clinically relevant pituitary adenomas has been reevaluated at 1/1064 of the population (1). Among them, prolactinomas represent the majority with a prevalence of 1/2000. They occur usually in females, aged 20–50 Y.O., and 80% are microadenomas. Nearly 5% of prolactinomas appear in a familial or genetic setting (MEN-1 or FIPA) (2). Cabergoline is proposed as the first line therapy and is usually efficient to normalize prolactin (PRL) l...

ea0088023 | Abstracts | BES2022

Is this just vitiligo? Nelson is hiding

Vis M De , S Deweer , B Velkeniers

Introduction: Autoimmune disease is a rare event occurring after remission of Cushing’s syndrome. We report on the appearance of new onset vitiligo in a patient treated for Cushing disease due to a an invasive pituitary adenoma, after bilateral adrenalectomy.Case report: A 64-year-old man presented to our endocrinology clinic with progressive lumbar pain that had developed two months earlier. He had undergone bilateral adrenalectomy for Cushing&#146...

ea0029p720 | Diabetes | ICEECE2012

A 52-week efficacy and safety profile of sitagliptin in Japanese type 2 diabetic patients in clinical settings

Matsuda A. , Hamada K. , Misaka A. , Matsuda M.

Background of Study: Some medications for the treatment of type 2 diabetes mellitus fail to achieve a continuous favorable glucose control in the long run during clinical use. Therefore we examined the durability of dipeptidyl peptidase-4 (DPP-4) inhibitor, sitagliptin which is relatively new to Japanese type 2 diabetic patients in clinical settings.Objectives and Methods: 117 subjects (M/F=65/52, Age: 66±10 y.o., duration of diabetes 12±8 y. b...

ea0029p849 | Endocrine tumours and neoplasia | ICEECE2012

Gene expression profile of LNCaP human prostate cancer cells after treatment with an antagonist of growth hormone-releasing hormone

Rekasi Z. , Czompoly T. , Zarandi M. , Schally A.

Antagonists of growth hormone-releasing hormone (GHRH-ant) may exert their antiproliferative effects directly on cancer cells, which are mediated by the tumoral GHRH receptors identified by us. Furthermore we showed that GHRH-ant are able to induce apoptosis in LNCaP human prostate cancer cells through a Ca2+-dependent pathway. However, the molecular features involved in the antiproliferative effect of GHRH-ant have not yet been elucidated. To study this, gene expression profi...

ea0027p74 | (1) | BSPED2011

Age at onset of inappropriate weight gain in Prader--Willi syndrome; an opportunity for obesity prevention

Abouof Noran , Shaikh M Guftar , Donaldson Malcolm

Background: Prader-Willi syndrome (PWS) results from loss of paternally imprinted gene(s) from the 15q 11-13 region and is characterised by weight faltering during early childhood due to hypotonia, followed by obesity due to onset of the hyperphagic phase.Aim of study: To determine the presence of an age zone during which excessive weight gain is particularly likely, in order to target counselling and dietary input.Method: Body mas...

ea0011p177 | Clinical practise and governance | ECE2006

Symptom-specific thresholds for testosterone deficiency modulate complaints and metabolic risk in 434 aging male patients

Zitzmann M , Faber S , Nieschlag E

Objective: The structure of psychological and somatic complaints of aging male patients in relation to sex hormone patterns and metabolism has not been fully elucidated, especially in regard to late-onset hypogonadism.Methods: We investigated the nature of complaints in 434 consecutive patients aged 50–86 years attending our andrology unit and their association with physical characteristics, life style habits and sex hormone levels.<p class="abs...

ea0011p290 | Diabetes, metabolism and cardiovascular | ECE2006

The impact of vitamins and/or minerals supplementation on blood pressure in type 2 diabetes

Farvid Maryam , Jalali M , Siassi F

Objective: The present study designed to assess the effect of Mg+Zn, vitamin C+E, and combination of these micronutrients on blood pressure in type 2 diabetic patients.Materials and methods: In a randomized, double-blind, placebo controlled clinical trial, 69 type 2 diabetic patients were randomly divided into four groups, each group receiving one of the following daily supplement for 3 months; group M: 200 mg and 30 mg Zn (n=16), group V: 200 mg...